Are Peptides Legal? Medicines, Research Use and Sport Rules

“Peptide” is a chemical description, not a legal category, so there is no single answer. A peptide can be an approved prescription medicine, a skincare ingredient, a laboratory chemical or an unapproved drug, and the law treats each differently. Regulators in the countries below look at what a product is intended for, which is shown by its marketing, rather than at its label. This article is about regulation and does not tell anyone what to buy or use.

Key points

• Approved peptide medicines such as semaglutide are prescription products with specific approved uses [8].
• A “research use only” label does not decide the legal status. FDA, Health Canada and Austria’s medicines agency each say the label does not remove a product from drug rules when other evidence shows human use [1][2][11][13].
• In the US, BPC-157 is not on any of FDA’s three 503A category lists as of 2026-05-14, and an FDA advisory committee voted 8 to 6 on 2026-07-23 to recommend adding it to the compounding list; FDA has not been shown to have acted on it [4][5][6].
• Many peptides are banned in sport under WADA classes S2 and S0, and BPC-157 is named in S0 [9].
• The sources speak mostly to sale and marketing. Few address possession by an individual [11][13][14].

This is information about regulation, not legal advice, and rules change. Dates below are those shown on each source.

What “legal” means for each kind of peptide

Product type	Typical status (source)
Approved medicine	Prescription-only label, approved indications [8]
Cosmetic ingredient	Cosmetic if intended to clean or beautify; a drug if intended to treat disease [7]
“Research use only” product	Treated as an unapproved drug when marketing shows human use [1][2]
Compounded drug (US)	Only under section 503A or 503B, with ingredient rules [3]
Sport	Prohibited under WADA S0 or S2 for athletes under the Code [9]

Approved peptide medicines

The Ozempic (semaglutide) label on DailyMed is a “Human Prescription Drug Label” and lists approved uses in adults with type 2 diabetes: blood-sugar control, cardiovascular risk reduction and kidney outcomes in people with chronic kidney disease (label revised 5/2026) [8]. That is the pattern for approved peptide drugs: a regulator reviews a specific product for specific uses, and a prescriber is involved. We opened only this label. We did not open labels for insulin, tirzepatide or GnRH analogues, so we make no claim about them beyond what the sport list below says about GnRH analogues.

Cosmetic peptides

FDA says a cosmetic is defined by intended use: articles intended to be “rubbed, poured, sprinkled, or sprayed on” or applied to the body to cleanse or beautify. It says cosmetics generally need no FDA approval before sale, except colour additives, and that a product intended to treat or prevent disease is a drug, even if it also affects appearance (page current as of 2025-11-18) [7]. The European Commission’s cosmetics page describes Regulation (EC) 1223/2009 as the framework for finished cosmetic products, with a manufacturer safety report and a one-time notification through the CPNP portal [15]. We did not open the regulation text and did not find a regulator page about a specific peptide in skincare, so this section covers the general rule only.

“Research use only” peptides

FDA’s warning letter of 2026-08-24 to Peak Performance Peptides (ref. 735127) concerns products including retatrutide, semaglutide, PT-141, tesamorelin and SS-31. FDA alleges they are unapproved new drugs under section 505(a) of the FD&C Act, and bases that on website wording describing the products as studied for effects such as glycemic control or sexual arousal. It says “research use only” and “not for human consumption” labels do not control, because the site’s evidence shows human use. It also points to a sterile solvent sold alongside the peptides as a means of preparing an injectable drug [1].

A letter of 2026-03-31 to Gram Peptides makes the same point for retatrutide and tirzepatide, citing weight-related claims on the firm’s site [2]. Both letters are FDA’s allegations against named firms, not court findings, and the letters ask for responses within 15 business days [1].

The distinction these letters draw is between selling a chemical for laboratory work and marketing the same chemical for people. For how analytical reports fit in, see what a peptide certificate of analysis does and does not prove and reading a certificate of analysis. A certificate says nothing about intended use.

Health Canada’s advisory of 2026-04-09 says “For Research Use Only” labelling “does not make these products legal or exempt from regulatory requirements,” and states that unauthorized drug products are illegal in Canada [11]. Austria’s medicines agency BASG (2026-05-27) says a “research chemical” label is irrelevant under pharmaceutical law, and that many such “peptides” are medicinal products without marketing authorisation [13].

Compounded peptides in the US

Pharmacies can compound under section 503A only with bulk ingredients that meet certain tests, including being on FDA’s list. While the list is incomplete, FDA’s interim policy sorts nominated substances into three categories. FDA says it does not intend to act against compounders using Category 1 substances if conditions are met; Category 2 substances carry significant safety risks and Category 3 had insufficient support, and for both FDA would consider enforcement under its general policies [3].

The category list updated 2026-05-14 shows [4]:

• Category 1 includes vasoactive intestinal peptide and GHK-Cu “except for injectable routes of administration.”
• Category 2 includes kisspeptin-10 and ibutamoren mesylate.
• Category 3 includes GHRP-2, GHRP-6, cibinetide and thymulin acetate.

For GLP-1 drugs, see compounded GLP-1 drugs: FDA rules explained.

Is BPC-157 legal?

In the US, the answer from FDA documents is “unresolved, and not approved.” BPC-157 does not appear on the 2026-05-14 lists of Category 1, 2 or 3 [4]. FDA’s safety-risks page (current 2026-04-22) lists it among substances previously in Category 2 but withdrawn by the nominators, and says compounded BPC-157 “may pose risk for immunogenicity for certain routes of administration” and that FDA lacks enough information to know whether it causes harm in humans [5]. On 2026-07-23 FDA’s Pharmacy Compounding Advisory Committee voted 8 to 6, with one abstention, to recommend adding BPC-157 to the 503A bulks list; the vote is non-binding and needs FDA action [6]. We did not find FDA’s decision, and it did not state whether pharmacies may compound it now. We found no approval of BPC-157 as a drug in any source we opened. That is a US answer only. Health Canada names it in a list of unauthorized products [11], and WADA names it as prohibited for athletes [9].

Are peptides banned in sport?

The WADA 2026 Prohibited List took effect on 2026-01-01. We read it in a copy hosted on a third-party site, because WADA’s own site would not load for us [9]. Two classes matter here:

• S2, peptide hormones, growth factors, related substances and mimetics, prohibited at all times (in and out of competition). It includes growth hormone fragments (examples: AOD-9604, hGH 176-191), growth hormone releasing factors (CJC-1295, sermorelin, tesamorelin, ipamorelin, ibutamoren), GHRPs, GnRH and its agonist analogues, kisspeptin, and growth factors including thymosin-beta-4 and derivatives such as TB-500 [9].
• S0, non-approved substances: any pharmacological substance with no current approval for human therapeutic use by a governmental health authority and not covered elsewhere on the list. S0 names BPC-157 as an example [9].

The list says its examples are “including, but not limited to.” MOTS-c and AICAR appear under S4 metabolic modulators in the same edition [9]; see our MOTS-c and AICAR overviews. A 2027 list, approved in September 2026, takes effect on 2027-01-01; a news item on it did not mention S2 peptide changes, but we did not read the list itself [10]. Sport bans apply to athletes under anti-doping rules, which are not criminal law.

Country by country

Jurisdiction	What we opened	What it says
United States (federal)	FDA letters, 503A pages, personal-importation page	Unapproved-drug enforcement against sellers [1][2]; categories for compounding [3][4]; personal import generally illegal with discretion [14]
Canada	Health Canada advisory, 2026-04-09	Unauthorized peptide drugs “illegal in Canada”; RUO labels no exemption [11]
UK	MHRA press release, 2026-05-29	Arrests “on suspicion of offences under the Human Medicines Regulations 2012” at a site believed to produce retatrutide, tirzepatide and peptide products [12]
Austria (EU/EEA)	BASG notice, 2026-05-27	Placing on the market and import prohibited for products classed as unauthorised medicinal products [13]

Possession, sale and import are separate questions. The FDA letters address interstate sale of products [1][2]. Health Canada states that selling is illegal and says it is working with the Canada Border Services Agency to stop unauthorized shipments, but does not address whether an individual may possess them [11]. BASG addresses placing on the market and import, says “purchasers” may face legal consequences, and does not address possession directly [13]. The MHRA release concerns manufacture and distribution [12].

Not checked: Australia (TGA), the EU-level framework (EMA, Directive 2001/83), Germany’s BfArM, and every country not listed. The TGA pages we tried did not open, so we make no statement on Australian scheduling.

Is it legal to import peptides?

For the US, FDA says that in most circumstances it is illegal for individuals to import drugs for personal use, with limited FDA discretion for serious conditions where effective treatment is not available in the US, subject to criteria such as a quantity of generally no more than three months and a doctor’s details or proof of an ongoing treatment (page current 2025-08-18) [14]. Health Canada reports seizures of unauthorized injectable peptides with border officials [11]. Austria says import of such products is prohibited [13]. We did not verify import rules for any other country. Import rules differ for each product and country, and we do not give guidance on importing.

Risks and unknowns

Legal status is not a safety finding in either direction. FDA says compounded BPC-157 lacks enough human information to judge harm [5], and its safety-risks page gives reasons such as immunogenicity and impurities for other peptides [5]. BASG says products from unofficial sources are not subject to official control, so quality, origin and effect cannot be guaranteed [13]. Things we could not establish: the outcome of FDA’s decision on BPC-157 after the July 2026 vote; the current Australian position; EU-wide rules; and whether any country criminalises personal possession. Enforcement statements are one regulator’s position at one date.

Frequently asked questions

Are peptides legal? It depends on the product and the country. Approved peptide medicines are legal as prescription drugs, cosmetics are regulated by intended use, and peptides sold for human use without approval are treated by FDA, Health Canada and BASG as unapproved or unauthorised drugs [1][7][8][11][13].

Are research peptides legal to buy? The sources we opened regulate sellers and marketing more than buyers. FDA, Health Canada and BASG say a research label does not change the status when marketing shows human use [1][11][13]. BASG says purchasers may face consequences [13]; Health Canada’s advisory did not address possession [11]. We found no US source on a buyer’s liability.

Is BPC-157 legal? It is not an approved drug in any source we opened. In the US it was withdrawn from FDA’s Category 2 in April 2026, is on no category list as of 2026-05-14, and was recommended for the bulks list by an advisory committee on 2026-07-23, pending FDA action [4][5][6]. It is prohibited in sport under S0 [9].

Are peptides banned in sport? Many are. WADA’s 2026 List prohibits peptide hormones and growth factors under S2, and non-approved substances including BPC-157 under S0, at all times [9].

Is it legal to import peptides? For the US, FDA says personal importation of unapproved drugs is illegal in most circumstances [14]. Austria prohibits import of unauthorised products [13]. We did not verify other countries.

Prices for research-use-only peptides across shops are on Peptilyze’s compound pages.

Sources

1. U.S. Food and Drug Administration, “Peak Performance Peptides, Warning Letter 735127” (2026-08-24). https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/peak-performance-peptides-735127-08242026. Used for unapproved-drug allegations, RUO label statement, the solvent product, response deadline.
2. U.S. Food and Drug Administration, “Gram Peptides, Warning Letter 721806” (2026-03-31). https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/gram-peptides-721806-03312026. Used for RUO disclaimer and intended-use findings.
3. U.S. Food and Drug Administration, “Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act” (content current 2026-05-14). https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act. Used for the category definitions and enforcement policy.
4. U.S. Food and Drug Administration, “Bulk Drug Substances Nominated for Use in Compounding Under Section 503A: categories 1, 2 and 3” (updated 2026-05-14). https://www.fda.gov/media/94155/download?attachment. Used for the named substances per category and the absence of BPC-157.
5. U.S. Food and Drug Administration, “Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks” (current 2026-04-22). https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks. Used for BPC-157 withdrawn entry and stated risks.
6. Good Morning America (ABC News), “FDA advisory committee votes to add popular peptide BPC-157” (2026-07-23). https://www.goodmorningamerica.com/wellness/story/fda-advisory-committee-votes-add-popular-peptide-bpc-134913891. News report, used for the 8-6 vote and non-binding status; FDA’s own record of the meeting was not opened.
7. U.S. Food and Drug Administration, “FDA Authority Over Cosmetics: How Cosmetics Are Not FDA-Approved, but Are FDA-Regulated” (current 2025-11-18). https://www.fda.gov/cosmetics/cosmetics-laws-regulations/fda-authority-over-cosmetics-how-cosmetics-are-not-fda-approved-are-fda-regulated. Used for the cosmetic and drug definitions.
8. DailyMed (U.S. National Library of Medicine), “Ozempic (semaglutide) injection, label” (revised 5/2026). https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=adec4fd2-6858-4c99-91d4-531f5f2a2d79. Used for prescription status and approved indications; only the first part of the page was read.
9. World Anti-Doping Agency, “International Standard Prohibited List 2026” (in force 2026-01-01), read in a copy hosted at https://www.asiarugby.com/wp-content/uploads/2026/06/2026list_en_final_clean_september_2025.pdf because wada-ama.org did not load. Used for S0, S2 and S4 text.
10. World Rugby, “WADA publishes 2027 Prohibited List” (2026-10-06). https://www.world.rugby/keep-rugby-clean/news/1048285/wada-publishes-2027-prohibited-list. Used for the 2027 list date; the list itself was not opened.
11. Health Canada, “Think twice before injecting peptides bought online: unauthorized products can seriously harm you” (2026-04-09). https://recalls-rappels.canada.ca/en/alert-recall/think-twice-injecting-peptides-bought-online-unauthorized-products-can-seriously-harm. Used for RUO label statement, illegal status, seizures.
12. UK Government (MHRA), “Two arrested during the MHRA’s largest ever seizure of unlicensed weight loss medicines” (2026-05-29). https://www.gov.uk/government/news/two-arrested-during-the-mhras-largest-ever-seizure-of-unlicensed-weight-loss-medicines. Used for the Human Medicines Regulations arrests; it does not mention research-use labels.
13. Austrian Federal Office for Safety in Health Care (BASG), “Peptides: illegal preparations from the internet with incalculable health risk” (2026-05-27). https://www.basg.gv.at/en/market-surveillance/official-announcements/detail/peptide-illegale-praeparate-aus-dem-internet-mit-unkalkulierbarem-gesundheitsrisiko. Used for the Austrian position.
14. U.S. Food and Drug Administration, “Personal Importation” (current 2025-08-18). https://www.fda.gov/industry/import-basics/personal-importation. Used for the US personal-importation rule.
15. European Commission, “Cosmetics legislation” (undated). https://single-market-economy.ec.europa.eu/sectors/cosmetics/legislation_en. Used for the description of Regulation (EC) 1223/2009 and CPNP notification.

Not verified, and not cited as fact: the TGA (Australia) pages on peptide scheduling and importing, which timed out; the EUR-Lex text of Directive 2001/83 and Regulation 1223/2009, which returned no content; WADA’s own site; the other 2026 FDA peptide warning letters seen only in search listings; MHRA statements about “research purposes” seen only in news coverage; the UK, Canadian and Australian court cases and Swissmedic’s campaign seen only in search results.

This article is information, not medical advice. This is not legal advice.